报价延迟最少15分钟:2026/04/04 02:28 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.24 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.36/0.65
|
|
企业价值
201.98M
|
| 资产负债 |
|
每股账面净值
0.65
|
| 现金流量 |
|
现金流量率
0.05
|
| 损益表 |
|
收益
103.12M
|
|
每股收益
6.67
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers. |
